Context Therapeutics grants director 45,000 stock options

Context Therapeutics Inc. director Karen L. Smith reported receiving a grant of stock options covering 45,000 shares of common stock.

Rhea-AI Filing Summary

Context Therapeutics Inc. director Karen L. Smith reported receiving a grant of stock options covering 45,000 shares of common stock. The options have an exercise price of $0.576 per share and expire on June 23, 2036.

According to the grant terms, the option vests and becomes exercisable on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders, subject to her continued service. Following this award, she holds options to acquire 45,000 shares directly.

Insider Trade Summary

Grant/Award: 45,000 shares

Grant/Award 1 txn

Insider Smith Karen L.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	45,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 45,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Key Figures

Option grant size: 45,000 shares Exercise price: $0.576 per share Expiration date: June 23, 2036 +3 more

6 metrics

Option grant size 45,000 shares Stock Option (right to buy) granted to director

Exercise price $0.576 per share Option exercise price for common stock

Expiration date June 23, 2036 Option expiration

Underlying shares 45,000 shares Common stock underlying granted option

Holdings after grant 45,000 derivative securities Total options held following transaction

Vesting date trigger June 24, 2027 One-year anniversary of grant; earlier vesting trigger

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, annual meeting of stockholders, exercise price

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders, subject to continued service"

exercise price financial

"conversion_or_exercise_price: 0.5760"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Context Therapeutics (CNTX) report for Karen L. Smith?

Context Therapeutics reported that director Karen L. Smith received a grant of stock options for 45,000 shares. These options are a compensation-related award rather than an open-market purchase or sale, and give her the right to buy common stock at a fixed exercise price.

How many Context Therapeutics (CNTX) shares are covered by the new stock options?

The reported stock option grant covers 45,000 shares of Context Therapeutics common stock. This means Karen L. Smith can potentially purchase up to 45,000 shares at the specified exercise price if the options vest and she chooses to exercise them.

What is the exercise price of Karen L. Smith’s Context Therapeutics (CNTX) options?

The stock options granted to Karen L. Smith have an exercise price of $0.576 per share. This is the fixed price at which she may buy Context Therapeutics common stock once the options have vested and before they expire in 2036.

When do Karen L. Smith’s Context Therapeutics (CNTX) stock options vest?

The options vest on the earlier of June 24, 2027 or Context Therapeutics’ 2027 annual meeting of stockholders. Vesting is also conditioned on her continued service with the company, meaning she must remain in her role through that time.

When do the newly granted Context Therapeutics (CNTX) stock options expire?

The stock options granted to Karen L. Smith expire on June 23, 2036. She may exercise vested options any time before that expiration date, subject to the plan terms and her continued eligibility under the award agreement.

Is Karen L. Smith’s Context Therapeutics (CNTX) Form 4 transaction a market buy or sell?

The Form 4 reports a grant of stock options, classified as a “Grant, award, or other acquisition.” It is not an open-market buy or sell but a compensation award that increases her potential future ownership through derivative securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Karen L.

(Last) (First) (Middle)

2001 MARKET STREET

SUITE 3915 UNIT #15

(Street)

PHILADELPHIA PENNSYLVANIA 19103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Context Therapeutics Inc. [ CNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.576	06/24/2026		A		45,000		(1)	06/23/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.

Remarks:

	/s/ Alex Levit, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)